araag2/HINT huggingface dataset:
Clinical trial NCT00308087 (phase 2, status: terminated)
Conditions: lymphoma, follicular
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: sargramostim (leukine), rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    terminated by sponsor due to low enrollment; see details below
  
Eligibility criteria:

        Inclusion Criteria (abbreviated list):

          -  Relapsed follicular B-cell lymphoma

          -  One or more previous therapies for non-Hodgkin's

          -  At least one measurable tumor by CT scan or MRI

          -  Additional criteria to be determined at screening visit

        Exclusion Criteria (abbreviated list):

          -  Rituximab refractory (less than 6 months from last treatment with rituximab to
             relapse)

          -  Currently receiving treatment for another cancer

          -  Infection currently being treated

          -  Active Hepatitis B

          -  History of HIV infection

          -  Pregnant

          -  Additional criteria to be determined at screening visit
Clinical trial NCT01175226 (phase 2, status: completed)
Conditions: rhinovirus
ICD codes: J20.6
Drugs: bta798, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects aged 18-70 years

          -  Diagnosis of asthma consistent with Global Initiative for Asthma (GINA) steps 1 to 3

          -  Presumptive human rhinovirus infection

        Exclusion Criteria:

          -  Current severe asthma exacerbation

          -  Severe asthma, GINA steps 4 or higher

          -  Uncontrolled or clinically significant medical condition, disease or event which could
             impact subject safety and/or study evaluations and/or compliance to the protocol

          -  Current smoker, ex-smoker of <1 year, or history of smoking >/=10 pack years.
Clinical trial NCT00531310 (phase 2, status: terminated)
Conditions: chronic myeloid leukemia
ICD codes: C92.11, C92.12, C92.21, C92.22, C92.10, C92.20
Drugs: reduced intensity conditioning, busulfan and fludarabine
SMILES: NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age: Patient must be less than 30 years of age.

          -  Consent: Patient or the patient's legally authorized guardian must be fully informed
             about their illness and the investigational nature of the study protocol (including
             foreseeable risks and possible side effects), and must sign an informed consent in
             accordance with the institutional policies approved by the U.S. Department of Health
             and Human Services.

          -  Organ Function: Patient must have adequate organ function as below Adequate renal
             function defined as:Serum creatinine 1.5 x normal, or Creatinine clearance or
             radioisotope GFR > 40 ml/min/m2 or >60 ml/min/1.73 m2 or an equivalent GFR as
             determined by the institutional normal range

          -  Adequate liver function defined as:Total bilirubin < 2.5 x normal; or SGOT (AST) or
             SGPT (ALT) < 5.0 x normal

          -  Adequate cardiac function defined as:

               -  Shortening fraction of >25% by echocardiogram, or

               -  Ejection fraction of >40% by radionuclide angiogram or echocardiogram

          -  Adequate pulmonary function defined as:

             -DLCO >40% by pulmonary function test For children who are uncooperative, no evidence
             of dyspnea at rest,no exercise intolerance, and a pulse oximetry >94% in room air.

          -  Disease Status

               -  Patients with CML with either of the following:

               -  Patients in 1st or 2nd chronic phase

               -  Patients in 1st or 2nd accelerated phase

        Exclusion Criteria:

          -  Patient in blast crisis

          -  Patient in 3rd or greater chronic phase

          -  Patient in 3rd or greater accelerated phase

               -  women that are pregnant are ineligible
Clinical trial NCT00193492 (phase 2, status: completed)
Conditions: lymphoma, follicular
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bevacizumab, rituximab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

        To be included in the study, you must meet the following criteria:

          -  Follicular NHL, grades 1 or 2 confirmed by a biopsy sample

          -  18 years of age or older

          -  Evidence of disease progression at time of study entry

          -  Must have had at least one previous chemotherapy regimen and not more than two
             previous chemotherapy regimens.

          -  Patients who have received previous rituximab are eligible as long as progression
             occurred more than six months following completion of previous rituximab therapy.

          -  Measurable or evaluable disease

          -  Able to perform activities of daily living without considerable assistance

          -  Adequate bone marrow, kidney, and liver function

          -  Signed informed consent obtained prior to initiation of any study-specific procedures
             or treatment.

        Exclusion Criteria:

        You cannot participate in the study if any of the following apply to you:

          -  Treatment with more than two previous chemotherapy regimens

          -  Prior treatment with bevacizumab or other similar agents

          -  Progressive NHL less than 6 months after receiving previous rituximab

          -  More than 1 prior treatment with investigational agents within 4 weeks prior to
             entering this study

          -  Spread of NHL to brain or nervous system

          -  History of any other uncontrolled or significant disease or medical condition that may
             put them at high risk for treatment complications with these agents

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have. You can then decide if you wish to
        participate.
Clinical trial NCT00220831 (phase 2/phase 3, status: terminated)
Conditions: diabetes, myocardial infarction, cardiovascular disease
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8, A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30
Drugs: natural source vitamin e 400iu/day
SMILES: CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C
Reason stopped: 
    interim analysis showed significant differences between two treatment groups
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diabetic patients aged 55 and above

        Exclusion Criteria:

          -  Patient who takes antioxidant treatment will be asked to stop, or can't be included in
             the study

          -  Patients who had a CVD incident (MI, Stroke, TIA), Unstable angina pectoris,
             Uncontrolled HTN, will have to wait a month after stabilization to be included in the
             study

          -  Allergy to Vitamin E
Clinical trial NCT00360035 (phase 2, status: completed)
Conditions: myelofibrosis
ICD codes: D75.81, C94.41, C94.42, C94.40
Drugs: obatoclax mesylate (gx15-070ms)
SMILES: COC1=CC(=N\C1=C/C1=C(C)C=C(C)N1)C1=CC2=CC=CC=C2N1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed myelofibrosis with myeloid metaplasia.

          -  No limitations on allowable type and amount of prior therapy.

          -  Patients must have normal organ function.

          -  Must be willing to submit to blood sampling for planned PK and PD analyzes.

          -  Must have ability to understand and willingness to sign a written informed consent
             form.

        Exclusion Criteria:

          -  No other agents or therapies administered with the intent to treat malignancy.

          -  Patients with prior exposure to obatoclax.

          -  Uncontrolled, intercurrent illness.

          -  Pregnant women and women who are breast feeding.
Clinical trial NCT00114764 (phase 2, status: completed)
Conditions: myeloid leukemia
ICD codes: C92.Z1, C92.Z2, C92.91, C92.92, C92.Z0, C92.90, C92.11
Drugs: filgrastim, pegfilgrastim
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
Eligibility criteria:

        Inclusion

          -  Histologically confirmed de novo AML as evidenced by absence of an antecedent
             hematologic disease of > 1 months duration, prior chemotherapy, prior radiation
             therapy or myelodysplastic cytogenetics (as per exclusion criteria)

          -  Life expectancy, with treatment, > 3 months

          -  Age > 18 years

          -  ECOG performance status 0, 1 or 2

          -  Adequate organ function to receive protocol specified chemotherapy

        Exclusion

          -  Subjects in blast transformation of chronic myeloid leukaemia (CML)

          -  Patients with secondary AML (Received previous chemotherapy or radiotherapy)

          -  Previous treatment for AML

          -  Patients with AML FAB type M3 (Acute Promyelocytic Leukemia, APL) or M7

          -  High risk (Unfavourable) cytogenetics [(-5/del(5q), -7/del(7q), t(8;21) with del (9q)
             or complex karyotype, inv(3q), abn 11q23, 20q, 21q, del(9q), t(6;9), t(9;22), abn 17p,
             complex karyotypes(>3 abnormalities)]
Clinical trial NCT01456052 (phase 2, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: telotristat etiprate, placebo
SMILES: CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C1=NC(N)=NC(O[C@H](C2=CC=C(Cl)C=C2N2C=CC(C)=N2)C(F)(F)F)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of ulcerative colitis of at least 6 months duration

          -  Disease extends at least 15 cm proximally from the anal verge, documented within the
             past 3 years

          -  Flare occurs on 5-aminosalicylic acid (5-ASA)/mesalamine therapy and subject is
             willing to remain on a stable dose for the duration of the study

          -  Age ≥18 and <70 years of age

          -  Able and willing to provide written informed consent

        Exclusion Criteria:

          -  Prior terminal ileum or colonic surgery, except appendectomy or hemorrhoid surgery

          -  Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious
             colitis, or clinical findings suggestive of Crohn's disease

          -  Clinical signs of fulminant colitis or toxic megacolon

          -  History of dysplasia associated lesion or mass (DALM)

          -  Subjects who have had surgery for ulcerative colitis, or in the opinion of the
             investigator, are likely to require surgery for ulcerative colitis during the study

          -  History of primary sclerosing cholangitis

          -  Any physical or laboratory abnormality deemed by the investigator as clinically
             significant

          -  Major surgery within 60 days of Screening

          -  Use of any investigational agent within 30 days of Screening or any therapeutic
             protein or antibody within 90 days of Screening
Clinical trial NCT00591851 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ac [adriamycin (a) (also known as doxorubicin) and cyclophosphamide (c)] followed by paclitaxel (p)
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  adenocarcinoma breast cancer

          -  ECOG performance status of 0 or 1

          -  peripheral neuropathy less than or equal to 1

          -  discontinued hormonal therapy as a chemoprevention while onstudy

          -  LVEF by MUGA > 55%?

          -  Absolute neutrophil count (ANC)> 1000/µL)

          -  platelet count > 100,000/µL)

          -  SGOT OR SGPT < 92.5 units/L

        Exclusion Criteria:

          -  Stage IV breast cancer

          -  any chemotherapy, radiation therapy, immunotherapy, or biotherapy for a CURRENT breast
             cancer

          -  pregnant or lactating patients

          -  active second malignancy, other than adequately treated non-melanoma skin cancers or
             in situ cervical cancer

          -  previous allergy/hypersensitivity to Doxorubicin, Cyclophosphamide, Paclitaxel, or
             other drugs formulated in Cremophor EL?

          -  unstable angina, congestive heart failure, current use of digitalis, beta-blockers, or
             calcium blockers for therapy of congestive heart failure, arrhythmia requiring medical
             therapy, or a history of a myocardial infarction within 12 months

          -  psychiatric illness that prevents her from understanding the nature of this study and
             complying with protocol requirements?

          -  active, unresolved infections

          -  sensitivity to E. coli derived proteins

          -  prior chemotherapy with an anthracycline

          -  prior Herceptin therapy
Clinical trial NCT01229215 (phase 2, status: completed)
Conditions: geographic atrophy
ICD codes: K14.1
Drugs: fcfd4514s, sham
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Willingness and ability to provide signed Informed Consent; in addition, at U.S.
             sites, Health Insurance Portability and Accountability Act (HIPAA) authorization, in
             other countries, as applicable according to national laws

          -  Well-demarcated area of GA secondary to age-related macular degeneration (AMD) in the
             absence of choroidal neovascularization (CNV)

        Exclusion Criteria:

          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for
             AMD in the study eye

          -  Previous subfoveal focal laser photocoagulation in the study eye

          -  Laser photocoagulation in the study eye

          -  Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary
             thermotherapy in the study eye

          -  GA in either eye due to causes other than AMD

          -  Diabetic retinopathy in either eye

          -  Active or history of wet AMD in either eye

          -  History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use an investigational drug or that might affect interpretation of
             the results of the study or that renders the patient at high risk for treatment
             complications

          -  Active malignancy or history of malignancy within the past 5 years

          -  Previous participation in any studies of investigational drugs within 3 months
             preceding Day 0
Clinical trial NCT00934518 (phase 2, status: withdrawn)
Conditions: squamous cell cancer of the head and neck
ICD codes: C96.20, C96.29, D47.09
Drugs: cetuximab
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Reason stopped: 
    inadequate patient accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a pathologically confirmed recurrence (reappearance of previously
             cleared) squamous cell cancer in the upper aerodigestive tract or a second squamous
             cell primary. Patients may have experienced more than one recurrence as long as the
             first recurrence occurred ≥6 months following the end of the prior RT.

          -  The recurrence or second primary must be confined to the head and neck above the
             clavicles (loco-regional recurrence).

          -  The majority (≥75%) of the tumor volume must have been in areas previously irradiated
             to ≥45 Gy. The previous irradiation must not exceed a maximum of 75 Gy.

          -  Patients must be at least 6 months from prior radiation therapy.

          -  If a resection is performed after the diagnosis of recurrence and before enrollment,
             either microscopic or macroscopic disease must be present (i.e. positive margins or
             gross residual).

          -  Karnofsky Performance Status 60-100.

          -  Granulocytes ≥ 1500/mm3, platelets ≥ 100,000/mm3, bilirubin ≤ 1.5 mg/dl, creatinine ≤
             1.5 mg/dl, within 6 weeks prior to registration.

          -  Must be able to submit previous radiation records (simulation and portal film if
             available) in order to assure that cord tolerance is not exceeded.

          -  Patients must sign a study-specific informed consent form prior to study entry.

          -  The patient must be between the ages of 18 and 75.

        Exclusion Criteria:

          -  Distant metastases.

          -  Completely resected recurrence with negative margins.

          -  Other concurrent invasive malignancies.

          -  Prior invasive malignancy unless disease free for at least two years (prior in situ
             malignancies are permissible).

          -  Intercurrent medical illnesses which would impair patient tolerance to therapy or
             limit survival.

          -  Pregnant and nursing women are excluded because of the potential teratogenic effects
             and potential unknown effects on nursing newborns.

          -  Previous treatment with cetuximab.
Clinical trial NCT02846428 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: 5-fluorouracil, capecitabine, cyclophosphamide, docetaxel, epirubicin
SMILES: FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Females with a unilateral, non-inflammatory, non-multicentric, non-metastatic breast
             adenocarcinoma, not considered candidates for conservative management, and whose
             diagnosis had been histologically confirmed as T2-3, N0-1, M0 according to the
             tumor-nodes-metastasis (TNM) classification

          -  Clinically or radiologically measurable lesion (in 2 dimensions)

          -  Eastern Cooperative Oncology Group (ECOG) performance Status less than equal to (<=) 1

        Exclusion Criteria:

          -  Females presenting with brain metastases or a neurological or psychiatric disorder
             which could interfere with proper treatment compliance

          -  Previous radiotherapy, chemotherapy, or hormonal therapy for breast cancer

          -  Previous history of a malignancy in last 5 years other than cutaneous basal cell
             carcinoma or carcinoma in situ of the uterine cervix

          -  Serious concomitant infection

          -  Pregnant or lactating females
Clinical trial NCT00132912 (phase 2, status: completed)
Conditions: arterial obstructive diseases, coronary disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: sch 530348
SMILES: [H][C@@]12C[C@]3([H])C[C@@H](CC[C@@]3([H])[C@H](\C=C\C3=CC=C(C=N3)C3=CC(F)=CC=C3)[C@]1([H])[C@@H](C)OC2=O)NC(=O)OCC
Eligibility criteria:

        Inclusion Criteria:

          -  A person who is 45 years or older and is mentally competent to provide a signed
             written informed consent.

          -  A person who is scheduled to undergo a percutaneous coronary intervention or a heart
             catheterization with the intent to undergo a percutaneous coronary intervention.

          -  If a woman is of childbearing potential (ie, before menopause), she must test negative
             for pregnancy and agree to use a reliable method of birth control.

        Exclusion Criteria:

          -  Pregnancy

          -  Recent stroke

          -  Active internal bleeding or a history of a bleeding disorder

          -  Increased risk of bleeding

          -  Severe high blood pressure

          -  Liver or kidney disease

          -  Low platelet count

          -  Condition such as alcoholism, mental illness, or drug dependence

          -  Ongoing chest pain

          -  Planned or ongoing treatment with a blood thinning medication

          -  A serious condition or illness that would interfere with participation in the study
Clinical trial NCT00637793 (phase 2, status: completed)
Conditions: xerostomia, sjogren's syndrome
ICD codes: M35.00, M35.01, M35.03, M35.0B, M35.02, M35.05, M35.08
Drugs: ngx267, ngx267, ngx267, ngx267
SMILES: CC[C@@H]1SC2(CCN(C)CC2)NC1=O, CC[C@@H]1SC2(CCN(C)CC2)NC1=O, CC[C@@H]1SC2(CCN(C)CC2)NC1=O, CC[C@@H]1SC2(CCN(C)CC2)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females aged 21 to 55 years, diagnosed with primary or secondary Sjögren's
             syndrome.

          -  Patients with a complaint of dry mouth based upon difficulty in speaking, swallowing,
             a sensation of mouth or throat dryness, lip or tongue dryness, or a level of thirst of
             sufficient intensity for the patient to seek therapy.

          -  Females of childbearing potential must not be at risk for pregnancy during the study.
             Females not of childbearing potential include postmenopausal and women who have been
             surgically sterilized.

          -  Patients must not be in an acute phase of illness.

        Exclusion Criteria:

          -  Patients who have clinically significant reduction kidney function. cardiovascular
             abnormalities; lymphoma secondary to Sjögren's syndrome; pulmonary disease; the
             presence of enlarged salivary glands; physical closure of the salivary gland or known
             surgical procedure on the lacrimal punctum.

          -  Patients with diagnoses of a current gastrointestinal (GI) disease that would be
             exacerbated by the use of cholinomimetics; a current and acute psychiatric disorder,
             acute iritis, narrow angle glaucoma, or retinal disease as determined by medical
             history and physical examination.

          -  Patients who are otherwise judged inappropriate for inclusion in the study by the
             investigator

          -  Patients who have received any experimental drugs or devices or participated in any
             clinical trial within 30 days prior to screening including participation in a previous
             NGX267 clinical trial.

          -  Patients who are allergic to compounds that are similar to NGX267.
Clinical trial NCT00484536 (phase 2, status: terminated)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: cdp323, placebo, cdp323
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was discontinued due to unfavorable interim analysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  relapsing form of MS

          -  screening EDSS score 0 - 5.5, inclusive

          -  at least one clinical relapse in the 12 months before screening

          -  active disease, defined by set of MRI activity criteria

          -  failed prior treatment with beta-interferons or glatiramer acetate

        Exclusion Criteria:

          -  signs of silent infections, including positive tests for HIV1, HIV2 or Hepatitis B or
             Hepatitis C or tuberculosis

          -  known allergy to gadolinium-DTPA, and/or ingredients of the study drug formulation

          -  pre-treatment with immunosuppressive or immunomodulatory drugs prior to screening
             within certain time frames